SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

3235-OMB Number: 0104

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and A	-	Requirin (Month/E	2. Date of Event Requiring Statement (Month/Day/Year) 07/29/2021 3. Issuer Name and Ticker or Trading Symbol RxSight, Inc. [RXST]							
(Last) (First) (Middle) C/O RXSIGHT, INC.					4. Relationship of Repor Issuer (Check all applicable)	5 ()	File	5. If Amendment, Date of Original Filed (Month/Day/Year)		
100 COLUMBIA			_		X Director Officer (give title below)	10% O Other (below)	6. li	6. Individual or Joint/Group Filing (Check Applicable Line)		
(Street) ALISO VIEJO	CA	92656			title below)	Delow)		X Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Inst 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
Ex			2. Date Exerce Expiration Day/	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	5. Ownership Form:	6. Nature of Indirect Beneficial	
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)		
Series G Preferred Stock		(1)	(1)	Common Stock	1,613,423	(1)	Ι	See footnote ⁽²⁾		
Series H Preferred Stock		(3)	(3)	Common Stock	242,013	(3)	Ι	See footnote ⁽²⁾		
Warrant (right to buy)		02/24/2017	(4)	Series H Preferred Stock ⁽³⁾	36,302 ⁽³⁾	12.4	I	See footnote ⁽²⁾		

Explanation of Responses:

1. All shares of the Series G Preferred Stock, par value \$0.001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value \$0.001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

2. Shares and warrant held by Longitude Venture Partners II, L.P. ("LVP II"). Longitude Capital Partners II, LLC ("LCP II") is the general partner of LVP II and may be deemed to have voting and investment power over the securities held by LVP II Patrick G. Enright and the Reporting Person are managing members of LCP II and may be deemed to share voting and investment power over the securities held by LVP II, LCP II and each of Mr. Enright and the Reporting Person disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests therein.

3. All shares of the Series H Preferred Stock, par value \$0.001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value \$0.001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.

4. The warrant shall be automatically exercised immediately prior to the closing of the Issuer's initial public offering of its Common Stock.

Remarks:

Exhibit 24 - Power of Attorney

/s/ Shelley Thunen, as Attorney-in-Fact

07/29/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of RxSight, Inc., Inc. (the "Company"), hereby constitutes and appoints Ron Kurtz, M.D., Shelley Thunen and Martin J. Waters the undersigned's true and lawful attorneys-in-fact to:

- complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-infact and agent shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of July, 2021.

Signature: /s/ Juliet Tammenoms Bakker Print Name: Juliet Tammenoms Bakker